Charlie Johannes, Ph.D.

Charlie Johannes brings to FogPharma more than two decades of experience in chemistry-driven platform technologies, therapeutic technology innovation and development of new modalities, especially hyperstabilized alpha-helical peptides. As vice president of exploratory chemistry, he oversees the exploratory chemistry underpinning our discovery efforts.

Prior to joining FogPharma, Charlie was a principal investigator for the peptide engineering program (PEP) at Singapore’s Agency for Science Technology and Research (A*STAR), where he led research collaborations with MSD on peptide permeability and worked in the disease intervention technology lab. Through these experiences, he targeted a multitude of macromolecular interactions such as p53, Bcl-2, eIF4E and KRAS. Charlie co-founded the Peptides and Proteins Society Singapore (P2S2) and served as the first president of the society from 2018 to 2021. While at A*STAR, Charlie was head of organic chemistry and responsible for directing a group of more than 50 scientists in the total synthesis of natural products, development of enantioselective methodologies, drug discovery, medicinal chemistry and process research. Prior to A*STAR, he developed two separate and successful diversity-oriented technology platforms at Forma Therapeutics and Infinity Pharmaceuticals that secured >$50 million in revenue and was responsible for external collaborations and support of medicinal chemistry efforts to fill the pipelines. Earlier in his career, Charlie worked in the New Leads Group at Eisai to rapidly advance natural product-based therapeutic leads.

Charlie also served as an adjunct assistant professor of chemistry at Nanyang Technological University with joint appointments at the Experimental Therapeutics Center and Experimental Drug Discovery Center. He has more than 50 publications and numerous patents.

Charlie trained as a synthetic organic chemist and earned his Ph.D. at Boston College.